177795-59-4

Basic information

• Product Name: (S)-Rabeprazole
• Synonyms: (S)-Rabeprazole;2-[(S)-[[4-(3-Methoxypropoxy)-3-Methyl-2-pyridinyl]Methyl]sulfinyl]-1H-benziMidazole
• CAS NO: 177795-59-4
• Molecular Formula: C18H21N3O3S
• Molecular Weight: 359.44264
• Product Categories: Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 177795-59-4.mol
• Article Data: 59

Chemical Properties

• Boiling Point: 603.9±65.0 °C(Predicted)
• Appearance: /
• Density: 1.33±0.1 g/cm3(Predicted)
• PKA: 9.57±0.10(Predicted)
• CAS DataBase Reference: (S)-Rabeprazole(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-Rabeprazole(177795-59-4)
• EPA Substance Registry System: (S)-Rabeprazole(177795-59-4)

Safety Data

• Hazardous Substances Data: 177795-59-4(Hazardous Substances Data)

Upstream product

• 117976-90-6 Rabeprazole sodium 
• 184713-27-7 1-Benzyloxymethyl-2-[4-(3-methoxy-propoxy)-3-methyl-pyridin-2-ylmethanesulfinyl]-1H-benzoimidazole 
• 117977-21-6 rabeprazole sulfide 
• 134469-07-1 Benzimidazol-2-thiol 
• 37699-43-7 2,3-dimethyl-4-nitropyridine N-oxide 
• 1589-49-7 methoxypropanol 
• 924663-40-1 2-[[(4-(3-methoxypropoxy)-3-methyl-pyridin-2-yl-1-oxide)methyl]sulfanyl]-1H-benzoimidazole 
• 408332-88-7 Diethyl tartrate 
• 13811-71-7 diethyl (2S,3S)-tartrate 
• 937-14-4 3-chloro-benzenecarboperoxoic acid 
• 924663-38-7 2-[[(RS)-(1H-benzimidazol-2-yl)sulfinyl]methyl]-4-(3-methoxypropoxy)-3-methylpyridine 1-oxide 
• 1080503-70-3 2,3-dimethyl-4-(3-methoxy-propoxy)pyridine 
• 1080503-68-9 (-)-menthyl 2-benzimidazolylsulphinate 
• 5038-11-9 N,N'-thiodimorpholine 

Downstream Products

• 924663-37-6 2-[(4-(3-methoxypropoxy)-3-methyl-pyridin-2-yl-1-oxide)methylsulfonyl]-1H-benzoimidazole 
• 259183-43-2 1-[[2-{2-(morpholin-4-yl)ethoxy}ethoxy]phenyl-4-sulfonyl]-2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole 

Relevant articles and documents

Method for preparing chiral sulfoxide drugs in water phase

The invention relates to the field of chiral drug preparation, in particular to a method for preparing chiral sulfoxide drugs in a water phase. The method for preparing the chiral sulfoxide drugs in the water phase comprises the following steps: using a hydrogen peroxide solution as oxidant, using a temperature-sensitive ferrocene chiral amino acid titanium complex as a catalyst and using prochiral thioether as a substrate in the pure water phase to perform an asymmetric oxidation reaction to synthesize the chiral sulfoxide drugs. The temperature-sensitive ferrocene chiral amino acid titaniumcomplex catalyst can be utilized to catalyze the asymmetric oxidation reaction of thioether in the pure water phase and has the characteristics of high catalytic efficiency and easy recovery of the catalyst.

Synthesis of Esomeprazole and Related Proton Pump Inhibitors through Iron-Catalyzed Enantioselective Sulfoxidation

We report here an application of iron catalysis for the kilogram scale asymmetric synthesis of a proton pump inhibitor, esomeprazole, in 87% yield and 99.4% ee by catalytic sulfoxidation with hydrogen peroxide using an iron salt/chiral Schiff base in combination with a carboxylate salt. Under similar reaction conditions, other proton pump inhibitors such as (S)-lansoprazole, (S)-rabeprazole, and (S)-pantoprazole, were also synthesized in high yield and ee. A carboxylate additive was crucial for the success of this reaction, and we consider that it coordinates to the active iron species, and it also acts as a hydrogen-bond acceptor to coordinate to the substrate through the imidazole NH.

INHIBITORS OF SARM1 NADase ACTIVITY AND USES THEREOF

The present disclosure provides compounds useful as inhibitors of SARM1 NADase activity, compositions thereof, and methods of using the same. The present disclosure provides compounds useful for treating a neurodegenerative or neurological disease or disorder, compositions thereof, and methods of using the same.